Issues related to international trade; Issues related to intellectual property protections for COVID-19 treatments; Issues related to the TRIPS Waiver; Global supply chain issues, including H.R. 2213/S. 998 - Medical Supply Chain Resiliency Act; Issues related to compulsory licensing and other intellectual property issues in multiple countries.
2025 · 4th Quarter (Oct 1 - Dec 31)
GILEAD SCIENCES, INC.
Filed by TIBER CREEK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 17, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK GROUP
- Client
- GILEAD SCIENCES, INC.
- Filing UUID
- eb82a4bb-8229-4864-85cf-b41218feea63
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to HIV prevention and procurement.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.